Clinical trial
A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin
NCT00481936 is registered in ClinicalTrials.gov with Sesen Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin
- Lead sponsor
- Sesen Bio, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 31, 2007
- Completion date
- April 30, 2008
- Enrollment
- 15 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.